BillionToOne laboratory
<p><strong><span class="legendSpanClass"><span class="xn-location">MENLO PARK</span></span> </strong>&#8212; <u>BillionToOne</u>, Inc., a molecular diagnostics company, has secured an additional <span class="xn-money">$48.5 million</span> of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to <span class="xn-money">$35 million</span>, with its existing lender, Bridge Bank. With this additional funding, the Company has raised over <span class="xn-money">$280 million</span> since its first commercial product launch just three years ago.</p>
<p>The <span class="xn-money">$48.5 million</span> funding consists of additional investments from Series C investors including Libertus Capital, Hummingbird Ventures, Baillie Gifford, Adams Street Partners, Neotribe Ventures, Fifty Years VC, Norwest Venture Partners, and Time BioVentures.</p>
<p>Since closing its <span class="xn-money">$125 million</span> Series C fundraising in <span class="xn-chron">March 2022</span>, BillionToOne says it has more than doubled its test volume and revenues. This additional funding, consisting of dilutive and non-dilutive capital, strengthens the Company&#8217;s liquidity position, increases its runway to the end of 2024, and provides it with the capital to execute on its growth strategy for both Prenatal and Oncology products. These funds will be used to continue to scale <u>UNITY Screen</u>, the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility, in addition to aneuploidies, and support the Company&#8217;s plan to commercialize its liquid biopsy product line, Northstar Select and Northstar Response, in early 2023.</p>
<p>&#8220;I am thrilled that our existing investors and Bridge Bank are aligned with our powerful vision to transform healthcare and believe we have the right technology and team to do it. This additional funding speaks to their continued belief in us. I am honored to have each of them as our partners on this journey,&#8221; said <span class="xn-person">Oguzhan Atay</span>, Ph.D., co-founder and CEO.</p>
<p>&#8220;We have partnered with BillionToOne since its early days and have witnessed the company&#8217;s tremendous growth. They have a distinguished technology platform that has been gaining momentum as is evident from the rapid scaling of its test volumes. We are excited to support their growth trajectory, as they build a category defining company across both prenatal and oncology,&#8221; said <span class="xn-person">Firat Ileri</span> from Hummingbird Ventures, a Board Member and one of the lead investors at BillionToOne.</p>
<p><span class="xn-person">Brian Kirkpatrick</span>, Vice President in Bridge Bank&#8217;s Life Sciences Group stated, &#8220;BillionToOne is truly differentiated in terms of its technology and talent. We have witnessed their perseverance as they continue to scale at a rapid pace. BillionToOne has a unique mix of technology and grit that is needed to maintain their accelerated pace of growth during these evolving financial times.&#8221;</p>
<p>BillionToOne was co-founded by <span class="xn-person">Oguzhan Atay</span>, Ph.D., and <span class="xn-person">David Tsao</span>, Ph.D.</p>

MOUNTAIN VIEW -- ALM Ventures has announced the launch of ALM Ventures Fund I, a…
SAN FRANCISCO -- Brainworks Ventures, an AI-native venture capital fund led by DARPA alumnus Dr.…
OpenAI is hiring Slack CEO Denise Dresser as the company's Chief Revenue Officer, overseeing global…
The Santa Clara County District Attorney’s Office has charged a San Jose 17-year-old with attempted…
SANTA CLARA — Lemurian Labs has secured $28 million in an oversubscribed Series A round,…
EMERYVILLE -- Ripple Foods, a producer of high-protein, allergen-free plant-based milks, has landed $17 million in…